161 related articles for article (PubMed ID: 10543754)
1. Activities of gemifloxacin (SB 265805, LB20304) compared to those of other oral antimicrobial agents against unusual anaerobes.
Goldstein EJ; Citron DM; Vreni Merriam C; Tyrrell K; Warren Y
Antimicrob Agents Chemother; 1999 Nov; 43(11):2726-30. PubMed ID: 10543754
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of gemifloxacin (SB 265805) against anaerobes.
Goldstein EJ; Citron DM; Warren Y; Tyrrell K; Merriam CV
Antimicrob Agents Chemother; 1999 Sep; 43(9):2231-5. PubMed ID: 10471570
[TBL] [Abstract][Full Text] [Related]
3. Review of the in vitro activity of gemifloxacin against gram-positive and gram-negative anaerobic pathogens.
Goldstein EJ
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():55-65. PubMed ID: 10824034
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.
Wexler HM; Molitoris E; Molitoris D; Finegold SM
Antimicrob Agents Chemother; 1996 Sep; 40(9):2232-5. PubMed ID: 8878617
[TBL] [Abstract][Full Text] [Related]
5. Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes.
Goldstein EJ; Citron DM; Merriam CV; Warren Y; Tyrrell K
Antimicrob Agents Chemother; 1999 Nov; 43(11):2801-5. PubMed ID: 10543769
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of gemifloxacin compared to seven other oral antimicrobial agents against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
Goldstein EJ; Conrads G; Citron DM; Merriam CV; Warren Y; Tyrrell K
Diagn Microbiol Infect Dis; 2002 Feb; 42(2):113-8. PubMed ID: 11858906
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.
Citron DM; Appleman MD
Antimicrob Agents Chemother; 2001 Jan; 45(1):345-8. PubMed ID: 11120995
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro activity of cefpodoxime against anaerobes other than Bacteroides fragilis.
Werner H; Heizmann WR; Höflsauer M
Infection; 1991; 19(5):377-9. PubMed ID: 1800380
[TBL] [Abstract][Full Text] [Related]
9. Synergic activity, for anaerobes, of trovafloxacin with clindamycin or metronidazole: chequerboard and time-kill methods.
Ednie LM; Credito KL; Khantipong M; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 2000 May; 45(5):633-8. PubMed ID: 10797085
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria.
Liebetrau A; Rodloff AC; Behra-Miellet J; Dubreuil L
Antimicrob Agents Chemother; 2003 Nov; 47(11):3667-71. PubMed ID: 14576144
[TBL] [Abstract][Full Text] [Related]
11. In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria.
Wexler HM; Molitoris E; Reeves D; Finegold SM
J Antimicrob Chemother; 1994 Oct; 34(4):579-84. PubMed ID: 7868409
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of Bay Y3118 against anaerobic bacteria.
Wexler HM; Molitoris E; Finegold SM
Antimicrob Agents Chemother; 1993 Nov; 37(11):2509-13. PubMed ID: 8285647
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activities of gemifloxacin, other quinolones, and nonquinolone antimicrobials against obligately anaerobic bacteria.
Kleinkauf N; Ackermann G; Schaumann R; Rodloff AC
Antimicrob Agents Chemother; 2001 Jun; 45(6):1896-9. PubMed ID: 11353648
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes.
Aldridge KE; Ashcraft D; Bowman KA
Antimicrob Agents Chemother; 1997 Feb; 41(2):484-7. PubMed ID: 9021215
[TBL] [Abstract][Full Text] [Related]
15. Comparison of activities of trovafloxacin (CP-99,219) and five other agents against 585 anaerobes with use of three media.
Hecht DW; Osmolski JR
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S44-50. PubMed ID: 8953106
[TBL] [Abstract][Full Text] [Related]
16. Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria.
Aldridge KE
Antimicrob Agents Chemother; 1994 Jul; 38(7):1671-4. PubMed ID: 7979307
[TBL] [Abstract][Full Text] [Related]
17. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria.
Ackermann G; Schaumann R; Pless B; Claros MC; Goldstein EJ; Rodloff AC
Eur J Clin Microbiol Infect Dis; 2000 Mar; 19(3):228-32. PubMed ID: 10795599
[TBL] [Abstract][Full Text] [Related]
18. Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens.
Goldstein EJ; Citron DM; Hudspeth M; Hunt Gerardo S; Merriam CV
J Antimicrob Chemother; 1998 Mar; 41(3):391-6. PubMed ID: 9578167
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.
Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
Antimicrob Agents Chemother; 1999 Nov; 43(11):2806-7. PubMed ID: 10543770
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
Citron DM; Merriam CV; Tyrrell KL; Warren YA; Fernandez H; Goldstein EJ
Antimicrob Agents Chemother; 2003 Jul; 47(7):2334-8. PubMed ID: 12821492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
